

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/644,370	08/20/2003	Gustavo E. Tamayo	6517-002	6417
22440	7590 06/09/2004		EXAM	INER
GOTTLIEB RACKMAN & REISMAN PC			FARAH, AHMED M	
270 MADISO 8TH FLOOR	ON AVENUE		ART UNIT	PAPER NUMBER
•	, NY 100160601		3739	

DATE MAILED: 06/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

·	Application No.	Applicant(s)					
	10/644,370	TAMAYO ET AL.					
Office Action Summary	Examiner	Art Unit					
	Ahmed M Farah	3739					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE three MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on							
Pa) This action is <b>FINAL</b> . 2b) ☑ This action is non-final.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-7 and 17-22</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-7 and 17-22</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/o	r election requirement.						
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
See the attached detailed Office action for a list of the detailed dopies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summar						
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	Paper No(s)/Mail D  5) Notice of Informal  6) Other:	Pate Patent Application (PTO-152)					
S. Patent and Trademark Office	ation Cumman.	test of Paper No /Mail Date 20040516					

Application/Control Number: 10/644,370

Art Unit: 3739

#### **DETAILED ACTION**

### **Double Patenting**

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 1-7 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 of U.S. Patent No. 6,470,078 (non-published yet). Although the conflicting claims are not identical, they are not patentably distinct from each other because they ere directed to a method for treating near vision defects of a patient's eye.

Application/Control Number: 10/644,370 Page 3

Art Unit: 3739

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by Rehse et al. U.S. patent 5,754,270.

Rehse et al. disclose multifocal lens designs that are configured as contact lenses or intraocular lenses for correcting presbyopia. In one embodiment of their invention, the lens is configured to form a peripheral optical zone in a cornea having a high refractive power to provide corrected near vision for the patient, the optical zone located peripheral to an concentric with a centrally located optical zone as presently claimed (Col. 6, lines 17-23).

As to claims 2-5, Table I (Col. 4, lines 26-35) and Figs. 4 and 5 of Rehse et al. depict the radial measurement of the central and peripheral optical zones for the preferred correction. Their peripheral optical zones meet the limitations of the instant claims.

4. Claims 17-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Swinger U.S. Pat. No. 5,647,865.

Art Unit: 3739

Swinger discloses a surgical laser and methods for correcting refractive disorders of the eye such as myopia and presbyopia by controlling the energy flux, beam diameter, and the exposure time of the treatment. He teaches that a multifocal lens is created in the cornea by appropriately distributing the laser energy over various optic zones such that the patient has a clear vision both for distant vision and for near vision. See the abstract; Col. 7, lines 10-20; and Col. 8, lines 30-34.

As to claim 17, the recitation that the 'controller is adapted to provide a peripheral ablation' is an intended use and has no structural limitations. Therefore, this recitation is not given a patentable weight.

In reference to claim 18, Swinger teaches that the diameter of the ablation varies depending on the procedure being performed, but it is usually greater in diameter than the critical central optically used zone of the cornea, which is typically in the range of 5-8 mm (see Col. 4, lines 52-57).

#### Conclusion

5. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. European patent 0201231 A2 to Holden et al. teaches a contact lens having a central distant vision zone and a peripheral near vision zone. See the abstract and claim 1.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ahmed M Farah whose telephone number is (703) 305-5787. The examiner can normally be reached on Mon-Thur. 9:30 AM-7:30 PM, and 9:30 AM - 6:30 PM on every other Friday.

Application/Control Number: 10/644,370 Page 5

Art Unit: 3739

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda C.M DVorak can be reached on (703) 308-0994. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A. Farah

Patent Examiner, AU 3739

05/16/2004